NEW YORK, Sept. 20, 2013 /PRNewswire/ -- Harwood Feffer LLP ( www.hfesq.com) is investigating potential claims against the board of directors of Transcept Pharmaceuticals, Inc. ("Transcept" or the "Company") (NASDAQ: TSPT) concerning the proposed acquisition of the Company by Retrophin, Inc. ("Retrophin").
Retrophin has offered to acquire Transcept for $4.00 per share. The Transcept board recently adoped a "tax benefit preservation plan" which may have been designed to stymie Retrophin's acquisition attempt.
Our investigation concerns whether the Transcept board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company shareholders.If you own Transcept shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact: Benjamin I. Sachs-Michaels, Esq. Robert I. Harwood, Esq.Harwood Feffer LLP488 Madison Avenue New York, New York 10022Phone Numbers: (877) 935-7400(212)935-7400Email: email@example.com Website: http://www.hfesq.com Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website ( http://www.hfesq.com) for more information about the firm. Attorney Advertising © 2013 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP ( www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. SOURCE Harwood Feffer LLP